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Abstract
Background: Serum levels of IGF-I in patients affected with multiple myeloma (MM) have been
scarcely studied. The present study is aimed to explore this point comparing 55 healthy subjects,
71 monoclonal gammopaties of uncertain significance (MGUS) and 77 overt MM patients. In the
same subjects, basic FGF and VEGF, have been detected. All three mediators were analyzed in
function of K-ras  mutation and melphalan response. Concerning IGF-I, two representative
monitoring examples have also been added.
Methods: Cytokine determinations were performed by commercially available ELISA kits, while
K12-ras mutation was investigated on genomic DNA isolated from bone marrow cell specimens by
RFLP-PCR assay.
Results: Significant reductions of IGF-I levels were observed in MGUS and MM as compared with
healthy controls. In addition, MM subjects showed significantly decreased serum IGF-I levels than
MGUS. Conversely, increasing levels were observed for bFGF and VEGF, molecules significantly
correlated. A multivariate analysis corrected for age and gender confirmed the significant difference
only for IGF-I values (P = 0.01). K12-ras mutation was significantly associated with malignancy,
response to therapy and with significantly increased serum bFGF levels.
Conclusion: IGF-I reduction in the transition: Controls→MGUS→MM and changes observed
over time suggest that IGF-I should be furtherly studied in future clinical trials as a possible
monitoring marker for MM.
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Background
In spite of the progresses recently registered in the therapy
of multiple myeloma (MM), the prognosis for patients
affected by this disease remains still poor [1]. MM demon-
strate a progressive, usually fatal, course with traditional
treatments, generally producing only temporary remis-
sions. A 5-year survival for MM patients is about 25% with
less than 5% alive subjects after 10 years [1].
Among innovative treatments, antiangiogenic therapy
seems to represent a promising approach, whose rationale
is based on tumour growth inhibition by starving cancer
cells of vital nutrients [2]. Recent evidences indicate that
angiogenic processes are increased and are fundamental
not only in solid tumours but also in hematologic dis-
eases, including MM, as well [3,4].
Scarce angiogenic activities have been found in mono-
clonal gammopathy of undetermined significance
(MGUS) as compared to the overt malignant forms, where
marrow neoangiogenesis parallels tumour progression
and correlates with poor prognosis, suggesting an angio-
genesis-dependent regulation of disease activity [5-7].
Neoangiogenesis is under the control of various
cytokines, that are expressed by neoplastic plasma cells, so
that their involvement in MM pathophysiology has been
strongly supported by different reports [8]. These modula-
tors include vascular endothelial growth factor (VEGF),
hepatocyte growth factor (HGF) and basic fibroblast
growth factor (bFGF), that have been extensively investi-
gated in biological samples derived from MM patients.
However, data concerning their potential prognostic
power as well as their reciprocal interactions are still con-
flicting [8-10] and remain to be better elucidated.
VEGF is a major regulator of tumour-associated angiogen-
esis exhibiting various biological activities, including reg-
ulation of embryonic stem cell development and local
generation of inflammatory cytokines [11]. VEGF gene
encodes for at least five isoforms which are anchored to
the extracellular matrix through the heparin-binding
domains. They are mitogenic to vascular endothelial cells
and induce vascular permeabilization [11]. VEGF expres-
sion is regulated by several factors including interleukins
(IL-1β, IL-6, IL-10), fibroblast growth factor (FGF-4) and
insulin-like growth factor1(IGF-1) [12].
bFGF is an 18 to 24 kD polypeptide, mainly produced by
cells of mesenchymal origin, which shares a key role of
mediator of angiogenesis with VEGF in vitro [13] and in
vivo [14]. This molecule is normally bound to heparin
and heparan sulphate proteoglycans in the extracellular
matrix, particularly in the basement membranes, around
vessels and stromal cells. It binds to a family of four dis-
tinct, high affinity tyrosine kinase receptors (FGFR-1–4)
and stimulates endothelial cell proliferation in vitro [13].
IGF-I is a mitogen and anti-apoptotic cytokine/growth
factor/hormone produced by several types of cells (fibrob-
lasts, hepatocytes, chondroblasts ..) [15]. Its potential role
as a growth factor for myeloma cells has been deeply ana-
lyzed and data of Ge NL et al [16] suggest that IGF-I signif-
icantly contributes to the expansion of MM cells in vivo by
activation of two distinct pathways: Akt/Bad and MAPK
kinase. Moreover, it has been suggested that circulating
levels of IGF-I and its inhibitory binding proteins (IGF-BP
1–6) may be associated with an increasing risk of com-
mon cancers [17]. The main circulating component of
IGF-I is released by the liver under GH control, while
locally, different regulatory mechanisms have been
reported [18,19]. Free IGF-I (molecules unbound to IGF-
BPs) acts through a specific high-affinity IGF-I receptor,
but also insulin receptor and IGF-II receptor may be used
although with lower affinities [20].
Recent data from the literature seem to support the idea of
a functional link existing between the induction of angio-
genesis-mediated growth factor expression and gene alter-
ations in tumour development. In particular, c-myc
deregulation by PDGF-BB has been demonstrated either
in normal [21] or in tumour cells [22]. Moreover, the
existence of a relationship between activation of ras onco-
genes and regulation of the VEGF/VPF expression has
been demonstrated in experimental [23] and clinical [24]
studies. In this regard, there are several reasons supporting
the fact that ras gene represents an interesting case for
studying the impact of cancer-associated genetic muta-
tions and tumour angiogenesis. In fact, activated ras is
capable of triggering several crucial signalling cascades, so
altering the expression of some members of ras-responsive
genes, many of which could be relevant for triggering or
contributing to tumour angiogenesis [25]. Although the
mechanisms governing the expression of angiogenic
cytokines in tumour cell by dominantly acting oncogenes
is largely unknown, the regulatory effect of oncogenes on
angiogenic mediators has some potentially important
therapeutic consequences and needs to be better investi-
gated, especially on hematologic malignancies.
Aim of the present study was to evaluate the serum levels
of a panel of three cytokines, such as IGF-I plus two ang-
iogenic factors such as VEGF and bFGF in 148 patients
with plasma cell dyscrasias. Seventy-one out of the total
were patients affected by MGUS and 77 were patients with
MM, these latter receiving treatment with conventional
chemotherapy (Melphalan/Prednisone). These two
groups of patients were compared with 55 controls repre-
sented by healthy human blood donors. In addition, we
tried to determine whether the serum levels of theseJournal of Experimental & Clinical Cancer Research 2009, 28:35 http://www.jeccr.com/content/28/1/35
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cytokines combined with the K-ras gene alterations might
allow to select groups of patients with different respon-
siveness to chemotherapy.
Methods
Patients and Controls
One hundred and forty-eight patients affected with plas-
macell dyscrasia were consecutively admitted to the
Regina Elena Cancer Institute of Rome and entered this
study. Fifty-five healthy blood donors were used as con-
trols. None of them showed any abnormalities concern-
ing basic laboratory tests and no detectable infection was
observed. Either patients or healthy blood donors were
admitted after giving informed consent.
The patient groups, whose main clinical features are
reported in Table 1, included 71 monoclonal gammapa-
thies of undetermined significance (MGUS) and 77 mul-
tiple myeloma (MM) diagnosed and staged according to
Durie & Salmon criteria [26]. MM patients were classified
as stage I or II when analysed at the onset of the disease
and were treated with conventional therapeutic regimens
including melphalan (0.25 mg/Kg body weight/day) and
prednisone (2 mg/Kg body weight) for 4 consecutive days.
The course was repeated at every 6th week until tumour
progression). The response was defined as minor response
when the serum M-protein had decreased by > 25% but <
50% or the urinary BJ had decreased by >50% but not to
< 0.2 g in 24 h. The non response group was defined by
serum M-protein levels that had decreased to < 25% or by
urine BJ protein levels that had decreased to < 50% of ini-
tial levels. Intermediate situations were categorized as a
no change disease.
Some of the myeloma patients, selected for having at least
6 subsequent determinations and from whom venous
samples had been drawn at regular intervals starting from
diagnosis, were included for a detailed analysis of the IGF-
I changes during the clinical course of the disease (about
2.5 years). Two representative examples are shown in Fig-
ure 1
Cytokine measurements
The detection of serum cytokines was performed on
peripheral blood samples processed within 1 h after veni-
puncture by centrifugation (1500 gfor 10 min) Serum
samples were collected from MGUS and MM patients as
well as from 55 healthy blood donors and were stored at
-70°C until testing. The angiogenic factors (VEGF and
bFGF) were measured with a quantitative ELISA (Quantik-
ine™ and Quantikine®; R&D Systems, Minneapolis, MN,
USA), according to the manufacturer's instructions and
expressed as pg/ml. All determinations were performed in
duplicate in only one analytical set; the ELISA test sensitiv-
ity, expressed as mean minimal detectable dose (MDD),
was < 5 pg/ml for VEGF and 3 pg/ml for bFGF. Coeffi-
cients of variation (CV) for the different cytokines
obtained repeating 5 times the same samples did not
exceed 15%. When necessary, samples with levels higher
than the maximum standard of the calibration curve were
repeated after dilution. The inter-assay CV reported by the
manufacturer varies from 6.2% to 8.8% for VEGF and
7.4% to 9.1% for bFGF. The intra-assay CV varies from
5.1% to 6.7% for VEGF and 3% to 9.7% for bFGF. In order
to avoid potential platelet interference with the VEGF con-
centration, for each patient or control subject the serum
values were corrected for their relative platelet counts.
IGF-I concentration was determined as serum immunore-
activity using a quantitative sandwich enzyme immu-
noassay (ELISA) technique (Quantikine® R&D Systems,
Minneapolis, MN, USA) according to the manufacturer's
instructions and expressed as ng/mL. Test sensitivity of
IGF-I was 0.026 ng/ml while the inter-assay CV reported
by the manufacturer for IGF-I vary from 7.5% to 8.1% and
the intra-assay CV from 3.5% to 4.3%.
DNA isolation
DNA was extracted from bone marrow aspirates using the
MICRO-GENO DNA kit (AB Analitica, Padoa, Italy)
according to the manufacturer's instructions. The quality
of isolated DNA was analyzed through a 1% agarose gel
electrophoresis.
Table 1: Main characteristics of MGUS, MM patients and healthy 
controls
Group (n) MGUS (71) MM (77) Control (55)
Gender
Male 38 49 28
Female 33 28 27
Age (y)
65.9 ± 10.5 66.7 ± 10.7 59.6 ± 14.5
Isotype (H)
IgG 62 48 --
IgA 3 28 --
IgM 6 -- --
IgD -- 1 --
Isotype (L)
K3 8 5 4 - -
λ 33 23 --
s-M Protein (g/L)
9.42 ± 4.61 25.8 ± 10.7 --
Bence Jones
Yes 41 63 --
No 30 14 --
Clinical stage (*)
-- I – II --
Age is given as mean ± SD. MGUS vs MM: p = 0.11; MGUS vs CTR: p 
= 0.005; MM vs CTR: p = 0.0001; Gender: MGUS vs MM: p = 0.30; 
MGUS vs CTR: p = 0.91; MM vs CTR: p = 0.21. s-M Protein 
concentration is expressed as mean ± SD. MGUS vs MM: p = 0.0001 
(*) according to the Durie & Salmon criteria [26].Journal of Experimental & Clinical Cancer Research 2009, 28:35 http://www.jeccr.com/content/28/1/35
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RFLP-PCR assay
Mutations at K-ras codon 12 (GGT→GCT) were detected
from all samples by an "enriched" restriction fragment
length polymorphism-polymerase chain reaction (RFLP-
PCR) assay according to Kahn SM et al. [27], as previously
described [28].
Statistical analysis
This report primarily employed univariate analysis of the
data by means of non parametric tests (Mann and Whit-
man or Kruskall Wallis variance analysis for quantitative
and corrected X square or Fisher's exact test for categorical
data).
Besides univariate analysis, a multivariate logistic regres-
sion analysis was also performed and the significances
were adjusted for age and gender. This logistic regression
analysis employed as end point the four variables subdi-
vided into two groups of subjects exceeding or not the cut
off value (i.e. the median value of the relative controls).
The multivariate logistic regression analysis has been
applied by using the SPSS version 6.0 for Microsoft Win-
dows 95/98. This model applies the stepwise logistic
regression ("SPSS backward LR method"). A p < 0.05 cut
off has been employed for the significance evaluation.
Results
Clinical characteristics of the subjects studied
To analyze the basal characteristics of the subjects studied
in this report (Table 1), we have tabulated the data con-
cerning the main clinical features subdivided into three
groups, namely: 55 healthy blood donors, 71 MGUS and
77 MM. No significant variations were registered for the
gender in the three comparisons, while age significantly
differed when control subjects were compared with
MGUS or MM.
Serum distributions of the four cytokines in Controls, 
MGUS and MM
The median serum levels and ranges of three cytokine:
IGF-I, bFGF and VEGF, compared with those of healthy
controls were reported in Table 2. The serum levels of IGF-
I were significantly and sequentially reduced from con-
trols to MGUS and from MGUS to MM. The significances
between these three groups were always < 0.0001. In addi-
tion, these significances were more pronounced than
those observed for bFGF and VEGF. A multivariate logistic
regression analysis showed that the significances observed
for IGF-I concentrations in the three groups were inde-
pendent of age and gender and the relative p was 0.01.
Also bFGF presented significantly different serum values
among the three groups. In particular, there was a statisti-
cally significant difference (p = 0.001) between the con-
trols and the MGUS patients, in which higher values were
observed. A similar difference was registered between the
controls and the MM patients (p = 0.02), while, in con-
trast, MGUS and MM showed similar results (p = 0.27).
The multivariate analysis, corrected for age and gender,
did not reach a statistical significance (p = 0.9).
VEGF, finally, did not show significant variations in the
four comparisons (p at least > 0.14) and the multivariate
analysis, performed as above, was also not significant (p =
0.08). A correlation matrix using the values of the four
variables in MGUS or MM groups only resulted significant
for VEGF vs b FGF (r = 0.37, p = 0.002) in MGUS patients.
K-ras mutations in the MGUS and MM patients
Since it is known that gene alterations may be linked with
cytokine modulation, we analyzed the incidence (%) of K-
ras  mutations in MGUS and MM subjects, due to the
emerging role of this gene in plasma cell dyscrasia patho-
genesis [29,30]. Mutations at K-ras codon 12 were ana-
lyzed on genomic DNA isolated from bone marrow cell
specimens of the two groups of patients. Due to the pres-
ence of low-molecular weight fragments of isolated DNA,
66 out of a total of 71 MGUS samples and 73 out of a total
Serial measurements of IGF-1 and serum M-Protein (s-MP)  from diagnosis (0) to last follow-up before death in two MM  patients Figure 1
Serial measurements of IGF-1 and serum M-Protein 
(s-MP) from diagnosis (0) to last follow-up before 
death in two MM patients. Serum MP concentrations 
were derived from medical records. The first arrow indicates 
when MP treatment started, according to the protocol 
described in "Methods; the others two arrows indicate the 
repetition of new cycles of therapy due to disease progres-
sion. [symbols: cube = IGF-I; diamond = s-M protein].
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of 77 MM samples were considered suitable for genetic
analyses.
The K-ras gene mutations were present in only one (1,5%)
MGUS subject and in twenty (27,4%) MM ones. As
expected, none of the control specimens analyzed mani-
fested gene alterations (Table 3). In fact, it was observed a
highly significant (p < 0.0001) difference between the
controls and MM or between MGUS and MM, while no
significance was found between controls and MGUS
groups (p = 0.95) by means of a two by two comparison
of the three groups (controls, MGUS and MM) concerning
the distribution of K-ras gene mutation,
Interestingly, significant increases (P = 0.02) of serum
bFGF levels were observed in patients showing K-ras gene
mutation (median = 4.6 pg/ml; range = 1.2–19.6 pg/ml)
as compared with those in which the gene was in the wild
type form (median = 2.2 pg/ml; range = 1.0–20.8 pg/ml).
No statistically significant differences between K-ras gene
status and serum factor concentrations were found for
IGF-I or VEGF.
MM response to Melphalan therapy
Seventy-three MM patients showing or not K-ras  gene
mutations were analyzed for their response to therapy. As
shown in Table 3, the presence of K-ras mutations was sig-
nificantly associated with a lower response to Melphalan
as compared with the wild type K-ras subjects (p = 0.015).
A statistically not significant trend (p = 0.07) was also
observed for the serum bFGF concentrations when com-
paring responders (mean = 1.9 pg/ml; range = 1.2–20.8
pg/ml) with non responders (mean = 3.8 pg/ml; range =
1.3–19.6 pg/ml).
In an attempt to find a link between the response to ther-
apy (yes/not), K-ras gene status (mutant/wild type) and
the cytokine level (greater or lower than cut-off), we could
only confirm the strong influence of K-ras  gene status
rather than the level of the four different cytokines in
determining the therapy response of MM patients (data
not shown).
Monitoring of two MM patients for Monoclonal 
component concentration and serum IGF-1 levels
Several patients were followed up during therapy. Figure 1
shows two of them presenting at least six/seven observa-
tion times in which consecutive serum samples from the
time of diagnosis until death were analyzed. The first
patient (panel A) had a high serum IGF-I (165 ng/ml)
level at diagnosis. He showed a minor response to treat-
ment for a least 15 months, with a 26% fall in serum M-
protein concentration and a concomitant slight reduction
of IGF-I amounts. Then new cycles of therapy were admin-
istered because of tumour progression. The patient
responded to treatment for about 10 months (s-M protein
= 6 g/l; serum IGF-I level = 101 ng/ml), then relapsed
again. New treatment was then initiated, but the patient
died after about 5 months.
The second patient (panel B), which had a normal serum
IGF-I (51 ng/ml) concentration at diagnosis, did not
respond to treatment and with the exception of an IGF-I
reduction observed 10 months after starting therapy, he
showed only slight modifications of both serum variables
during the course of disease.
Discussion and conclusion
MM evolution has been shown to be strongly conditioned
by angiogenic mechanisms in terms of growth and ther-
apy sensitivity. Several authors tried to explain how ang-
iogenic cytokines [4,31] may work influencing the MM
cells; consequently, in the recent years, the presence and
quantity of several angiogenic factors, their inducers and
their signalling mediators have been documented in an
effort to explore the possibility to use them as diagnostic,
monitoring or prognostic markers of disease evolution
and therapy sensitivity.
Despite this bulk of information, clear indications have
not been completely gained and some different contrast-
ing results have been published [4,8,9,32-34]. In general,
angiogenic mediators (VEGF, basic FGF, TGF-beta1, TNF-
alpha) have been found to be increased in MM patients
and often significantly correlated each to the others [8].
Sometimes, they were also stage related, although not all
the reports were consistent in this field. Angiogenic factors
Table 2: Serum levels of IGF-I, betaFGF and VEGF in Control, 
MGUS and MM
Group N° IGF-I
ng/ml
B-FGF
pg/ml
VEGF
pg/ml
Controls 55 135.5
(65–279)
1.62
(1.04–2.15)
1.25
(0.15–1.95)
MGUS 71 111.3
(10–215.8)
2.08
(0.04–8.19)
1.12
(0.15–5.90)
MM 77 78
(16–352)
2.37
(0.04–82.7)
1.37
(0.3–18.3)
P1 <.0001 0.01 0.19
P2 -- <.0001 .001 .57
P3 -- <.0001 .27 .14
P4 -- <.0001 .02 .14
A statistical analysis has been performed both on the three groups 
together and on the different couple of groups.
Cytokine levels are given as median (range). P1 = univariate analysis, 
Kruskall-Wallis test on the three groups. P2 = univariate analysis, 
Mann Whitney test on Controls vs MGUS. P3 = univariate analysis, 
Mann Whitney test on MGUS vs MM. P4 = univariate analysis, Mann 
Whitney test on Controls vs MM.
The IGF-I behaviour has been also confirmed by logistic regression 
analysis after data correction for age and gender, as described in the 
text.Journal of Experimental & Clinical Cancer Research 2009, 28:35 http://www.jeccr.com/content/28/1/35
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also show different behaviours under treatment. Interest-
ingly, while conventional therapy (melphalan plus pred-
nisolone) reduced the serum concentrations of these
factors [35], an anti-angiogenic therapy based on thalido-
mide plus dexamethasone was accompanied by increase
of the same factors in the responder subjects [4,34].
Another molecule involved in MM biology is IGF-I, a
mediator with cytokine (locally)/hormone (in the general
circulation) activity [36], known to be a growth promoter
for several tumours, including MM, acting through its
anti-apoptotic/proliferative [16,19,37] effects and interac-
tion with angiogenic factors, such as the anti-proliferative
TGF-beta1 [38].
Surprisingly, serum data regarding IGF-I and MM are very
scarce and partially contrasting [39,40] although IGF-I is
suspected to be able to transform MGUS in MM [41]. Pre-
vious data on B-cell chronic lymphocytic leukaemia have
found a clear reduction of IGF-I in sera as compared with
controls [42], even though the studies were initially
expected to exibit increased concentrations, due to the
tumourigenic activity of IGF-I. This is not so surprising in
that the IGF-I determinations were obtained from sera of
subjects already affected with MM.
It is known that all cancers, including MM, possess a more
or less strong inflammatory component (in particular the
proinflammatory cytokines IL-6 and TNF-alpha are pro-
duced by myeloma cells) and that inflammation is associ-
ated with reduced IGF-I synthesis [43]. Data from
literature showed that IGF-I molecules may be modulated
by SOCS genes, after their activation by proinflammatory
cytokines [37].
The present study clearly shows that the serum IGF-I con-
centrations significantly decreased from healthy blood
donors to MGUS and to MM patients, a finding not previ-
ously described. This result was also independent of age
(significantly lower in controls) and sex, as confirmed by
multivariate regression analysis, both in all subjects and
when only IgG MM patients were considered (data not
shown). A similar analysis, obtained separately in male or
female patients, confirmed our findings (data not
shown), indicating that gender was not the cause of the
differences previously described. These findings open the
possibility that IGF-I molecule might be further studied as
a monitoring marker to follow the patients over time by
specific trials.
A previous study by Standal and coworkers [39], failed to
observe significant differences between MM and controls.
Such divergence may depend on some patient characteris-
tics. For example, Standal selected only patients with 69%
of advanced tumour stages (III), while our patients were
prevalently of tumour stages I and II. As previously men-
tioned, chronic B cell leukaemia showed data similar to
those reported in our paper [42].
Opposite to IGF-I was the behaviour of VEGF and bFGF,
whose concentrations were increased in MM sera as com-
pared with control samples. VEGF and b-FGF serum con-
centrations were highly correlated (P = 0.002), confirming
the results previously published by other authors [8].
Another variable considered in this study was the K-ras
gene whose mutation was significantly associated with the
malignancy [29,30], while no significant difference was
observed between controls and MGUS. K-ras gene altera-
tion has previously been associated with the modulation
of different biological agents, including IGF-I
[23,24,44,45]. As reported for solid tumours [47], we
found significant increases of serum bFGF concentrations
in MM patients eliciting K-ras gene activation. Moreover,
the same K12-ras mutation was significantly associated
with increased resistance to the therapy (Table 3). A trend
in lower serum bFGF levels was observed when respond-
ers MM patients were compared with the non responder
ones. When K12-ras  mutation and the levels of the 3
cytokines under or above cut offs were combined, no sig-
nificant differences were found in the different subgroups
(data not shown). Therefore, therapy effect was only
dependent on K-ras mutation and not on cytokine levels.
Considering the results of the present study, we tried to
evaluate the possibility that IGF-I might be used as moni-
toring marker. Therefore, we show two representative
examples of MM patients followed during subsequent
Table 3: K-ras gene status and response to therapy
Group K12-ras gene mutation/total (%) Positive therapy response (%) P
Value
Mutant Wild type
Controls 0/75 (0) __ __ __
MGUS 1/66 (1.5) __ __ __
MM 20/73 (27.4) 26.9 58.3 0.01
Statistical significance for K12-ras gene mutation: Control vs MGUS p = 0.95, Control vs MM p = 0.0001, MGUS vs MM p < 0.0001, Positive therapy 
response: minor response and no change disease (see Methods).Journal of Experimental & Clinical Cancer Research 2009, 28:35 http://www.jeccr.com/content/28/1/35
Page 7 of 8
(page number not for citation purposes)
courses of therapy and whose disease behaviour was
related to the monoclonal component concentrate on and
serum IGF-I levels over time.
These results show that, generally, serum IGF-I concentra-
tions behave similarly to the monoclonal component.
Some of the divergences observed may be explained by
the fact that various eveniences may influence the serum
IGF-I levels: age and gender [47], inflammatory processes
[48], other concomitant diseases [49,50], endocrine dis-
eases [47], nutrition [47], drug administration and liver
toxicity. Furthermore, melphalan therapy, which is hepa-
totoxic and therefore should reduce IGF-I synthesis, has
been reported to increase IGF-I molecules after the 4th
course [40], possibly when it was effective in restoring the
peripheral blood IGF-I amounts. It is also possible to
speculate that the cytotoxic effect of therapy should
release a great amount of endocellular molecules from
necrotic cells with induction of inflammatory processes
and IGF-I drop.
In conclusion, as previously reported for other neoplastic
diseases [42,51], serum IGF-I concentrations are clearly
reduced in case of open disease. Therefore, a clinical use
of serum determinations of this molecule should be made
very carefully since this substance does not show a clear
specificity for MM. A possible role of IGF-I as putative
monitoring marker of malignant disease seems to emerge
by our study, even though specific clinical trials need to be
planned and the possible interference of other factors in
serum determinations should be considered.
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